Ayako Ojima
Overview
Explore the profile of Ayako Ojima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsui T, Ojima A, Higashimoto Y, Taira J, Fukami K, Yamagishi S
Oncol Lett
. 2015 Dec;
10(4):2644-2648.
PMID: 26622904
Caveolin-1 (Cav), a primary protein component of caveolae, is overexpressed in prostate cancer, thereby promoting growth and metastasis of this tumor. By contrast, pigment epithelium-derived factor (PEDF) has been shown...
2.
Maeda S, Matsui T, Ojima A, Suematsu M, Kaseda K, Higashimoto Y, et al.
Ophthalmic Res
. 2015 Oct;
54(4):175-80.
PMID: 26492350
Purpose: Abnormalities in electroretinograms (ERG), such as reduced amplitudes and delayed implicit times of a- and b-wave and oscillatory potentials (OPs), are one of the earliest features of diabetic retinopathy...
3.
Matsui T, Nakashima S, Nishino Y, Ojima A, Nakamura N, Arima K, et al.
Lab Invest
. 2015 Mar;
95(5):525-33.
PMID: 25730373
Advanced glycation end products (AGEs) and their receptor (RAGE) have a role in diabetic nephropathy. We have recently found that linagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP-4), could inhibit renal...
4.
Kan H, Yamagishi S, Ojima A, Fukami K, Ueda S, Takeuchi M, et al.
J Clin Lab Anal
. 2014 Sep;
29(6):480-4.
PMID: 25252033
Background: The prevalence of non-B or non-C hepatocellular carcinoma (NBNC-HCC) has been increasing all over the world. Advanced glycation end products (AGE) play a role in the pathogenesis of alcoholic...
5.
Maeda S, Matsui T, Ojima A, Takeuchi M, Yamagishi S
Nutr Res
. 2014 Sep;
34(9):807-13.
PMID: 25241332
Advanced glycation end products (AGEs) not only inhibit DNA synthesis but also play a role in diabetic retinopathy by evoking apoptosis and inflammation in retinal pericytes via interaction with a...
6.
Yamagishi S, Ishibashi Y, Ojima A, Sugiura T, Matsui T
Int J Cardiol
. 2014 Jul;
176(2):550-2.
PMID: 25065332
No abstract available.
7.
Matsui T, Nishino Y, Ojima A, Maeda S, Tahara N, Yamagishi S
Am J Pathol
. 2014 Feb;
184(4):1094-1103.
PMID: 24530621
Oxidative stress and inflammation in the adipose tissues contribute to the metabolic syndrome. Pigment epithelium-derived factor (PEDF) inhibits vascular inflammation through its anti-oxidative properties. However, it remains unclear whether PEDF...
8.
Ojima A, Matsui T, Maeda S, Takeuchi M, Inoue H, Higashimoto Y, et al.
Lab Invest
. 2014 Feb;
94(4):422-9.
PMID: 24514068
Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced...
9.
Ojima A, Oda E, Higashimoto Y, Matsui T, Yamagishi S
Int J Cardiol
. 2014 Jan;
171(3):443-6.
PMID: 24439773
Background: Advanced glycation end products (AGE) and their receptor (RAGE) interaction elicit inflammatory and proliferative reactions in arteries, thus playing a role in cardiovascular disease. We have recently found that...
10.
Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Maeda S, et al.
Ophthalmic Res
. 2013 Oct;
50(4):221-6.
PMID: 24081217
Background/aims: Vildagliptin is an oral inhibitor of dipeptidyl peptidase-4, an enzyme mainly responsible for inactivating incretins, and one of the widely used drugs for the treatment of type 2 diabetes....